The Natus Medical Incorporated (BABY) Upgrade to “Buy” at the Zacks Investment Research

The Natus Medical Incorporated (BABY) Upgrade to “Buy” at the Zacks Investment Research

Natus Medical Incorporated (NASDAQ:BABY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The brokerage currently has a $41.00 price target on the stock. Zacks Investment Research’s price objective suggests a potential upside of 8.61% from the company’s previous close. According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep…

The West Marine, Inc. (WMAR) Lowered to “Sell” at the Zacks Investment Research

The West Marine, Inc. (WMAR) Lowered to “Sell” at the Zacks Investment Research

West Marine, Inc. (NASDAQ:WMAR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday. According to Zacks, “West Marine, Inc. is the largest specialty retailer of recreational and commercial boating supplies and apparel in the United States. They have three divisions (Stores, Wholesale (Port Supply), and Catalog), which all sell after-market recreational boating supplies directly to customers. They are also engaged, through its Port Supply business line and their stores, in the wholesale distribution of products to commercial customers…

The Westlake Chemical Corporation (WLK) Stock Rating Upgrade by the Zacks Investment Research

The Westlake Chemical Corporation (WLK) Stock Rating Upgrade by the Zacks Investment Research

Westlake Chemical Corporation (NYSE:WLK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The firm presently has a $65.00 price target on the stock. Zacks Investment Research’s price objective would suggest a potential upside of 9.69% from the stock’s previous close. According to Zacks, “Westlake Chemical Corporation is a vertically integrated international manufacturer and supplier of petrochemicals, polymers and fabricated products. The company’s range of products includes ethylene, polyethylene, styrene, vinyl intermediates, PVC, PVC Pipe, PVC windows, fence and…

The Willdan Group, Inc. (WLDN) Lowered by the Zacks Investment Research

The Willdan Group, Inc. (WLDN) Lowered by the Zacks Investment Research

Willdan Group, Inc. (NASDAQ:WLDN) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a research note issued on Wednesday. According to Zacks, “Willdan Group is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. Nationwide, they enable their clients to realize cost and energy savings by providing a wide range of specialized services. They assist their clients with a broad range of complementary services relating to: Energy Efficiency and Sustainability; Engineering and Planning;…

The Workiva Inc. (WK) Stock Rating Decreased by the Zacks Investment Research

The Workiva Inc. (WK) Stock Rating Decreased by the Zacks Investment Research

Workiva Inc. (NYSE:WK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday. According to Zacks, “Workiva LLC offers a cloud-based and mobile-enabled platform for enterprises to collect, manage, report and analyze critical business data in real time. The company provides solutions for compliance, risk, sustainability and management reporting as well as enterprise risk management. It serves the manufacturing and materials, energy and utilities, financial services, healthcare, media and entertainment, real estate, retail, consumer goods,…

The Synovus Financial Corp Has $1,340,000 Position in Applied Materials, Inc. (AMAT)

The Synovus Financial Corp Has $1,340,000 Position in Applied Materials, Inc. (AMAT)

Synovus Financial Corp raised its position in shares of Applied Materials, Inc. (NASDAQ:AMAT) by 134.4% during the third quarter, Holdings Channel reports. The institutional investor owned 44,473 shares of the manufacturing equipment provider’s stock after buying an additional 25,496 shares during the period. Synovus Financial Corp’s holdings in Applied Materials were worth $1,340,000 as of its most recent SEC filing. Several other institutional investors have also made changes to their positions in the stock. UMB Bank N A MO increased its stake in shares of Applied Materials by 7.6% in…

The UBS Asset Management Americas Inc. Has $1,370,000 Stake in Boyd Gaming Corporation (BYD)

The UBS Asset Management Americas Inc. Has $1,370,000 Stake in Boyd Gaming Corporation (BYD)

UBS Asset Management Americas Inc. increased its position in Boyd Gaming Corporation (NYSE:BYD) by 16.5% during the third quarter, Holdings Channel reports. The institutional investor owned 69,258 shares of the company’s stock after buying an additional 9,786 shares during the period. UBS Asset Management Americas Inc. owned 0.06% of Boyd Gaming Corporation worth $1,370,000 as of its most recent SEC filing. Other large investors also recently modified their holdings of the company. Nisa Investment Advisors LLC increased its stake in shares of Boyd Gaming Corporation by 1.7% in the second…

The SPX FLOW, Inc. (FLOW) Shares Bought by the UBS Asset Management Americas Inc.

The SPX FLOW, Inc. (FLOW) Shares Bought by the UBS Asset Management Americas Inc.

UBS Asset Management Americas Inc. boosted its stake in SPX FLOW, Inc. (NYSE:FLOW) by 1.6% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 44,071 shares of the company’s stock after buying an additional 700 shares during the period. UBS Asset Management Americas Inc. owned approximately 0.11% of SPX FLOW worth $1,363,000 at the end of the most recent reporting period. Several other hedge funds and other institutional investors have also recently bought and sold shares of FLOW. First Mercantile Trust Co….

The Insider Buying: Tecogen Inc. (TGEN) Director Buys 25,000 Shares of Stock

The Insider Buying: Tecogen Inc. (TGEN) Director Buys 25,000 Shares of Stock

Tecogen Inc. (NASDAQ:TGEN) Director Charlest Maxwell purchased 25,000 shares of the company’s stock in a transaction dated Friday, January 6th. The shares were acquired at an average price of $4.00 per share, for a total transaction of $100,000.00. Following the purchase, the director now directly owns 129,769 shares of the company’s stock, valued at approximately $519,076. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Charlest Maxwell also recently made the following trade(s): Tecogen Inc. (NASDAQ:TGEN) traded down 6.48%…

The Actuant Corporation (ATU) EVP Eugene Edward Skogg Sold 4,339 Shares

The Actuant Corporation (ATU) EVP Eugene Edward Skogg Sold 4,339 Shares

Actuant Corporation (NYSE:ATU) EVP Eugene Edward Skogg sold 4,339 shares of the firm’s stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $26.60, for a total transaction of $115,417.40. Following the completion of the transaction, the executive vice president now directly owns 103,652 shares in the company, valued at $2,757,143.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Actuant Corporation (NYSE:ATU) traded up 1.13% during mid-day trading on Wednesday, reaching…

The James R. Gochee Sold 4,000 Shares of New Relic, Inc. (NEWR) Stock

The James R. Gochee Sold 4,000 Shares of New Relic, Inc. (NEWR) Stock

New Relic, Inc. (NYSE:NEWR) insider James R. Gochee sold 4,000 shares of the business’s stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $31.17, for a total transaction of $124,680.00. Following the transaction, the insider now owns 372,990 shares in the company, valued at $11,626,098.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. New Relic, Inc. (NYSE:NEWR) traded up 0.16% during midday trading on Wednesday, reaching $31.22. 238,513 shares of the company’s…

The Oppenheimer Holdings, Inc. Reaffirmed Outperform Rating for the Mueller Water Products (MWA)

The Oppenheimer Holdings, Inc. Reaffirmed Outperform Rating for the Mueller Water Products (MWA)

Mueller Water Products (NYSE:MWA)‘s stock had its “outperform” rating reiterated by analysts at Oppenheimer Holdings, Inc. in a note issued to investors on Wednesday. They currently have a $15.00 target price on the stock. Oppenheimer Holdings, Inc.’s target price points to a potential upside of 14.07% from the stock’s current price. Other research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Mueller Water Products from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research…

The Global Payments Inc. (GPN) Earns “Outperform” Rating from the Oppenheimer Holdings, Inc.

The Global Payments Inc. (GPN) Earns “Outperform” Rating from the Oppenheimer Holdings, Inc.

Global Payments Inc. (NYSE:GPN)‘s stock had its “outperform” rating restated by Oppenheimer Holdings, Inc. in a report issued on Wednesday. They presently have a $88.00 target price on the stock, up from their previous target price of $85.00. Oppenheimer Holdings, Inc.’s price objective would indicate a potential upside of 12.49% from the stock’s current price. Other equities research analysts also recently issued reports about the company. Zacks Investment Research downgraded Global Payments from a “buy” rating to a “hold” rating in a report on Wednesday, November 23rd. Royal Bank Of…

The Xylem Inc. (XYL) Stock Rating Reaffirm by the Oppenheimer Holdings, Inc.

The Xylem Inc. (XYL) Stock Rating Reaffirm by the Oppenheimer Holdings, Inc.

Xylem Inc. (NYSE:XYL)‘s stock had its “outperform” rating reaffirmed by investment analysts at Oppenheimer Holdings, Inc. in a research report issued on Wednesday. They presently have a $56.00 price target on the stock, down from their prior price target of $58.00. Oppenheimer Holdings, Inc.’s price target suggests a potential upside of 13.36% from the company’s current price. XYL has been the subject of a number of other research reports. Northcoast Research began coverage on Xylem in a research note on Thursday, November 17th. They issued a “buy” rating for the…

The Enbridge Energy Management LLC (EEQ) Upgraded to Buy at the Zacks Investment Research

The Enbridge Energy Management LLC (EEQ) Upgraded to Buy at the Zacks Investment Research

Enbridge Energy Management LLC (NYSE:EEQ) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The brokerage currently has a $29.00 target price on the stock. Zacks Investment Research’s price target would suggest a potential upside of 10.10% from the company’s current price. According to Zacks, “Enbridge Energy Management is a Delaware limited liability company. They manage and control the business and affairs of Enbridge Partners. They have no assets or operations other than those related to…

The Diamondrock Hospitality Company (DRH) Stock Rating Upgrade by the Zacks Investment Research

The Diamondrock Hospitality Company (DRH) Stock Rating Upgrade by the Zacks Investment Research

Diamondrock Hospitality Company (NYSE:DRH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday. The firm presently has a $13.00 target price on the real estate investment trust’s stock. Zacks Investment Research’s price target points to a potential upside of 15.25% from the stock’s previous close. According to Zacks, “DiamondRock Hospitality Company is a self-advised real estate company that owns, acquires and invests in upper upscale and upscale hotel properties located primarily in North America. To a lesser extent, it…

The CorMedix Inc. (CRMD) Lowered by the Zacks Investment Research

The CorMedix Inc. (CRMD) Lowered by the Zacks Investment Research

CorMedix Inc. (NYSEMKT:CRMD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday. According to Zacks, “CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company’s therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests)…

The Zacks Investment Research Downgrade California Resources Corporation (CRC) to Sell

The Zacks Investment Research Downgrade California Resources Corporation (CRC) to Sell

California Resources Corporation (NYSE:CRC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday. According to Zacks, “California Resources Corporation is engaged in exploration and production of oil and gas. The Company produces, gathers, processes and markets crude oil, natural gas, natural gas liquids and electricity primarily in the State of California. California Resources Corporation is based in Los Angeles, California. “ Separately, Morgan Stanley upgraded California Resources Corporation from an “underweight” rating to an “equal weight” rating and upped…

The Canon, Inc. (CAJ) Upgraded to “Strong-Buy” at the Zacks Investment Research

The Canon, Inc. (CAJ) Upgraded to “Strong-Buy” at the Zacks Investment Research

Canon, Inc. (NYSE:CAJ) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday. The brokerage currently has a $33.00 price target on the stock. Zacks Investment Research’s target price suggests a potential upside of 14.46% from the company’s current price. According to Zacks, “Canon, Inc. is an industry leader in professional and consumer imaging equipment and information systems. Canon’s extensive product line enables businesses and consumers worldwide to capture, store and distribute visual information. Canon…

The Investment Analysts’ Upgraded for the January, 11th (AKBA, BABY, BATS, BEAV, BKD, BWXT, CAJ, CM, DAN, DRH)

The Investment Analysts’ Upgraded for the January, 11th (AKBA, BABY, BATS, BEAV, BKD, BWXT, CAJ, CM, DAN, DRH)

Investment Analysts’ upgrades for Wednesday, January 11th: Akebia Therapeutics (NASDAQ:AKBA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $12.00 price target on the stock. According to Zacks, “Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “ Natus Medical (NASDAQ:BABY) was upgraded by analysts at Zacks Investment Research from a…